Direct oral anticoagulant treatment of deep vein thrombosis reduces IL‑6 expression in peripheral mono‑nuclear blood cells

Candido,Saverio; Lumera,Giovanni; Barcellona,Giuliana; Vetri,Davide; Tumino,Elda; Platania,Ingrid; Frazzetto,Evelise; Privitera,Graziella; Incognito,Carmela; Gaudio,Agostino; Signorelli,Salvatore Santo

doi:10.3892/etm.2020.9367

Direct oral anticoagulant treatment of deep vein thrombosis reduces IL‑6 expression in peripheral mono‑nuclear blood cells

Authors:
- Saverio Candido
- Giovanni Lumera
- Giuliana Barcellona
- Davide Vetri
- Elda Tumino
- Ingrid Platania
- Evelise Frazzetto
- Graziella Privitera
- Carmela Incognito
- Agostino Gaudio
- Salvatore Santo Signorelli
View Affiliations

Affiliations: Department of Biomedical and Biotechnological Sciences, Oncologic, Clinic and General Pathology Section, University of Catania, I‑95123 Catania, Italy, Department of Clinical and Experimental Medicine, University of Catania, I‑95123 Catania, Italy, Internal Medicine Division, University Hospital ‘G. Rodolico’, I‑95123 Catania, Italy
Published online on: October 21, 2020 https://doi.org/10.3892/etm.2020.9367
Article Number: 237

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Multiple factors play a pathophysiologic role for the venous thromboembolism (VTE) as a multi‑factorial disease. Inflammation might play a peculiar role in shifting towards a pro‑thrombotic state. Anticoagulant drugs are the first cure line for VTE. The low‑molecular‑weight heparins (LMWH) show anti‑coagulant capability as well as reducing levels of inflammatory factors, including interleukin (IL)‑6. The direct oral anticoagulants (DOACs) have shown efficacy in threating VTE, additionally to the anti‑activated factor X these drugs seem able to reduce the abnormal release of pro‑inflammatory agents. The present study evaluated the capability of DOACs in reducing plasma level of IL‑6 in patients suffered from deep vein thrombosis (DVT) of the lower limbs. Our results showed reduced IL‑6 expression levels in the peripheral lymphocytes of DVT compared to controls (fold‑change, 2.8; P<0.05). We postulate that lowered IL‑6 expression in the lymphocytes of DVT patients may mediate the anti‑inflammatory action of DOACs. The present study is the first evidence concerning the anti‑inflammatory properties of DOACs in specific setting of VTE patients such as DVT.

View Figures

View References

1	Mackman N: New insights into the mechanisms of venous thrombosis. J Clin Invest. 122:2331–2336. 2012.PubMed/NCBI View Article : Google Scholar
2	Branchford BR and Carpenter SL: The role of inflammation in venous thromboembolism. Front Pediatr. 6(142)2018.PubMed/NCBI View Article : Google Scholar
3	Riva N, Donadini MP and Ageno W: Epidemiology and pathophysiology of venous thromboembolism: Similarities with atherothrombosis and the role of inflammation. Thromb Haemost. 113:1176–1183. 2015.PubMed/NCBI View Article : Google Scholar
4	Prandoni P: Links between arterial and venous disease. J Intern Med. 262:341–350. 2007.PubMed/NCBI View Article : Google Scholar
5	Smeeth L, Cook C, Thomas S, Hall AJ, Hubbard R and Vallance P: Risk of deep vein thrombosis and pulmonary embolism after acute infection in a community setting. Lancet. 367:1075–1079. 2006.PubMed/NCBI View Article : Google Scholar
6	Tichelaar YI, Kluin-Nelemans HJ and Meijer K: Infections and inflammatory diseases as risk factors for venous thrombosis. A systematic review. Thromb Haemost. 107:827–837. 2012.PubMed/NCBI View Article : Google Scholar
7	Tang N, Li D, Wang X and Sun Z: Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia. J Thromb Haemost. 18:844–847. 2020.PubMed/NCBI View Article : Google Scholar
8	Klok FA, Kruip MJHA, van der Meer NJM, Arbous MS, Gommers DAMPJ, Kant KM, Kaptein FHJ, van Paassen J, Stals MAM, Huisman MV, et al: Incidence of thrombotic complications in critically ill ICU patients with COVID-19. Thromb Res. 191:145–147. 2020.PubMed/NCBI View Article : Google Scholar
9	Saha P, Humphries J, Modarai B, Mattock K, Waltham M, Evans CE, Ahmad A, Patel AS, Premaratne S, Lyons OTA, et al: Leukocytes and the natural history of deep vein thrombosis: Current concepts and future directions. Arterioscler Thromb Vasc Biol. 31:506–512. 2011.PubMed/NCBI View Article : Google Scholar
10	Phillippe HM: Overview of venous thromboembolism. Am J Manag Care. 23:S376–S382. 2017.PubMed/NCBI
11	Reitsma PH, Versteeg HH and Middeldorp S: Mechanistic view of risk factors for venous thromboembolism. Arterioscler Thromb Vasc Biol. 32:563–568. 2012.PubMed/NCBI View Article : Google Scholar
12	Chirinos JA, Heresi GA, Velasquez H, Jy W, Jimenez JJ, Ahn E, Horstman LL, Soriano AO, Zambrano JP and Ahn YS: Elevation of endothelial microparticles, platelets, and leukocyte activation in patients with venous thromboembolism. J Am Coll Cardiol. 45:1467–1471. 2005.PubMed/NCBI View Article : Google Scholar
13	Levi M, van der Poll T and Büller HR: Bidirectional relation between inflammation and coagulation. Circulation. 109:2698–2704. 2004.PubMed/NCBI View Article : Google Scholar
14	Franco RF, de Jonge E, Dekkers PE, Timmerman JJ, Spek CA, van Deventer SJ, et al: The in vivo kinetics of tissue factor messenger RNA expression during human endotoxemia: Relationship with activation of coagulation. Blood. 96:554–559. 2000.PubMed/NCBI
15	Malaponte G, Polesel J, Candido S, Sambataro D, Bevelacqua V, Anzaldi M, Vella N, Fiore V, Militello L, Mazzarino MC, et al: IL-6-174 G > C and MMP-9-1562 C > T polymorphisms are associated with increased risk of deep vein thrombosis in cancer patients. Cytokine. 62:64–69. 2013.PubMed/NCBI View Article : Google Scholar
16	Zhang Y, Zhang Z, Wei R, Miao X, Sun S, Liang G, Chu C, Zhao L, Zhu X, Guo Q, et al: IL (Interleukin)-6 contributes to deep vein thrombosis and is negatively regulated by miR-338-5p. Arterioscler Thromb Vasc Biol. 40:323–334. 2020.PubMed/NCBI View Article : Google Scholar
17	Streiff MB, Agnelli G, Connors JM, Crowther M, Eichinger S, Lopes R, McBane RD, Moll S and Ansell J: Guidance for the treatment of deep vein thrombosis and pulmonary embolism. J Thromb Thrombolysis. 41:32–67. 2016.PubMed/NCBI View Article : Google Scholar
18	Martinelli I, Bucciarelli P and Mannucci PM: Thrombotic risk factors: Basic pathophysiology. Crit Care Med. 38 (Suppl):S3–S9. 2010.PubMed/NCBI View Article : Google Scholar
19	Shaheen K, Alraies MC, Alraiyes AH, Christie R and Factor V: Leiden: How great is the risk of venous thromboembolism? Cleve Clin J Med. 79:265–272. 2012.PubMed/NCBI View Article : Google Scholar
20	Shiqing W, Shengzhong M, Cheng Z, Guangqing C and Chunzheng G: Efficacy of low molecular weight heparin in spinal trauma patients after part concentrated screw surgery and its influence on blood parameters and the incidence of deep venous thrombosis. Med Hypotheses. 132(109330)2019.PubMed/NCBI View Article : Google Scholar
21	Cirino G, Cicala C, Bucci M, Sorrentino L, Ambrosini G, DeDominicis G and Altieri DC: Factor Xa as an interface between coagulation and inflammation. Molecular mimicry of factor Xa association with effector cell protease receptor-1 induces acute inflammation in vivo. J Clin Invest. 99:2446–2451. 1997.PubMed/NCBI View Article : Google Scholar
22	Borensztajn K, Peppelenbosch MP and Spek CA: Factor Xa: At the crossroads between coagulation and signaling in physiology and disease. Trends Mol Med. 14:429–440. 2008.PubMed/NCBI View Article : Google Scholar
23	Bukowska A, Zacharias I, Weinert S, Skopp K, Hartmann C, Huth C and Goette A: Coagulation factor Xa induces an inflammatory signalling by activation of protease-activated receptors in human atrial tissue. Eur J Pharmacol. 718:114–123. 2013.PubMed/NCBI View Article : Google Scholar
24	Esmon CT: Targeting factor Xa and thrombin: Impact on coagulation and beyond. Thromb Haemost. 111:625–633. 2014.PubMed/NCBI View Article : Google Scholar
25	Kikuchi S, Tsukahara K, Sakamaki K, Morita Y, Takamura T, Fukui K, Endo T, Shimizu M, Sawada R, Sugano T, et al: Comparison of anti-inflammatory effects of rivaroxaban vs. dabigatran in patients with non-valvular atrial fibrillation (RIVAL-AF study): Multicenter randomized study. Heart Vessels. 34:1002–1013. 2019.PubMed/NCBI View Article : Google Scholar
26	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.PubMed/NCBI View Article : Google Scholar
27	Kyrle PA and Eichinger S: Deep vein thrombosis. Lancet. 365:1163–1174. 2005.PubMed/NCBI View Article : Google Scholar
28	Signorelli SS, Malaponte MG, Di Pino L, Costa MP, Pennisi G and Mazzarino MC: Venous stasis causes release of interleukin 1beta (IL-1beta), interleukin 6 (IL-6) and tumor necrosis factor alpha (TNFalpha) by monocyte-macrophage. Clin Hemorheol Microcirc. 22:311–316. 2000.PubMed/NCBI
29	Kremers BMM, Ten Cate H and Spronk HMH: Pleiotropic effects of the hemostatic system. J Thromb Haemost. 16:1464–1473. 2018.PubMed/NCBI View Article : Google Scholar
30	Brinkmann V: Neutrophil extracellular traps in the second decade. J Innate Immun. 10:414–421. 2018.PubMed/NCBI View Article : Google Scholar
31	Fuchs TA, Brill A, Duerschmied D, Schatzberg D, Monestier M, Myers DD Jr, Wrobleski SK, Wakefield TW, Hartwig JH and Wagner DD: Extracellular DNA traps promote thrombosis. Proc Natl Acad Sci USA. 107:15880–15885. 2010.PubMed/NCBI View Article : Google Scholar
32	Brill A, Fuchs TA, Savchenko AS, Thomas GM, Martinod K, De Meyer SF, Bhandari AA and Wagner DD: Neutrophil extracellular traps promote deep vein thrombosis in mice. J Thromb Haemost. 10:136–144. 2012.PubMed/NCBI View Article : Google Scholar
33	Savchenko AS, Martinod K, Seidman MA, Wong SL, Borissoff JI, Piazza G, Libby P, Goldhaber SZ, Mitchell RN and Wagner DD: Neutrophil extracellular traps form predominantly during the organizing stage of human venous thromboembolism development. J Thromb Haemost. 12:860–870. 2014.PubMed/NCBI View Article : Google Scholar
34	Konstantinides SV, Meyer G, Becattini C, Bueno H, Geersing GJ, Harjola VP, Huisman MV, Humbert M, Jennings CS, Jiménez D, et al: 2019 ESC Guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ERS). Eur Heart J. 41:543–603. 2020.PubMed/NCBI View Article : Google Scholar
35	Shi C, Wang C, Wang H, Yang C, Cai F, Zeng F, Cheng F, Liu Y, Zhou T, Deng B, et al: The potential of low molecular weight heparin to mitigate cytokine storm in severe COVID-19 patients: A retrospective cohort study. Clin Transl Sci: Sep 3, 2020 (Epub ahead of print).
36	Jeraj L, Jezovnik MK and Poredos P: Rivaroxaban versus warfarin in the prevention of post-thrombotic syndrome. Thromb Res. 157:46–48. 2017.PubMed/NCBI View Article : Google Scholar
37	Bhalla V, Lamping OF, Abdel-Latif A, Bhalla M, Ziada K and Smyth SS: Contemporary meta-analysis of extended direct-acting oral anticoagulant thromboprophylaxis to prevent venous thromboembolism. Am J Med. 133:1074–1081.e8. 2020.PubMed/NCBI View Article : Google Scholar
38	Borgel D, Bianchini E, Lasne D, Pascreau T and Saller F: Inflammation in deep vein thrombosis: A therapeutic target? Hematology. 24:742–750. 2019.PubMed/NCBI View Article : Google Scholar